Latest / The Well-Built Life / Metformin's Mystery: Can It Slow Aging?
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell, alongside Thomas Bennett, and we are so glad
- 0:07Speaker 1: you are tuning in. We are here to cut through
- 0:09Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:13Speaker 1: share simple practical habits that help you feel stronger, healthier,
- 0:17Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:21Speaker 1: and let's dive in. Let's dive into metformin, a powerhouse
- 0:25Speaker 1: drug with a long history and a newfound role in
- 0:27Speaker 1: healthy aging research. It's been around for decades, but its
- 0:31Speaker 1: potential in longevity is making waves.
- 0:34Speaker 2: Right, and that's the crucial nuance here. It's interesting how
- 0:38Speaker 2: a drug meant primarily for type 2 diabetes is now
- 0:41Speaker 2: catching the attention of researchers who are looking at broader
- 0:44Speaker 2: health outcomes. Rachel, what first caught your eye about metformin's
- 0:48Speaker 2: potential in aging?
- 0:50Speaker 1: Well, Thomas metformin has this interesting mechanism of action. It
- 0:54Speaker 1: works by influencing how cells use energy. It targets mitochondria,
- 0:59Speaker 1: and activates something called AEMP, which in turn affects METTOR
- 1:03Speaker 1: and enhances autophagy. It's like it's fine-tuning the cell's metabolic
- 1:07Speaker 1: processes to maybe slow down the aging process.
- 1:10Speaker 2: Exactly. And the way it does that by modulating insulin
- 1:13Speaker 2: function is quite fascinating. It reduces glucose production by the
- 1:18Speaker 2: liver and enhances insulin sensitivity. That's a big deal, especially
- 1:23Speaker 2: since insulin resistance is closely linked to aging. But the
- 1:27Speaker 2: effects on gene expression through epigenetic changes, that's where things
- 1:31Speaker 2: get a bit murky.
- 1:33Speaker 1: True, epigenetic changes might slow the aging clock, but we
- 1:37Speaker 1: are still playing a guessing game with humans. We can't
- 1:40Speaker 1: directly observe the changes happening at the cellular level in
- 1:43Speaker 1: real time. And while worms and mice show increased lifespan
- 1:48Speaker 1: and reduced biological age markers, those results aren't necessarily translating
- 1:53Speaker 1: to humans just yet.
- 1:54Speaker 2: That's a fair point. The studies on worms and mice
- 1:57Speaker 2: are compelling, but humans are far more complex. The 40-month
- 2:02Speaker 2: study with male sinomolgus monkeys showed some promise but no
- 2:05Speaker 2: clear evidence of extended lifespan. And the human studies that
- 2:09Speaker 2: do exist mostly show linkages between metformin and longer survival
- 2:14Speaker 2: and reduced age-related illnesses. But these are observational.
- 2:18Speaker 1: Let's not forget the side effects. Long-term use can lead
- 2:21Speaker 1: to things like nausea, diarrhea, and a risk of vitamin
- 2:25Speaker 1: B12 deficiency. And for those with weakened kidneys, the risk
- 2:29Speaker 1: of lactic acidosis needs to be monitored closely. It's a
- 2:33Speaker 1: fine line, right?
- 2:34Speaker 2: Absolutely. And this leads us to the current research like
- 2:37Speaker 2: the MEMIM trial, which found metformin reduced the incidence of
- 2:41Speaker 2: type 2 diabetes, but didn't prevent other health issues like
- 2:44Speaker 2: cancer or heart disease. The TAME project, on the other hand,
- 2:49Speaker 2: is in the works and aims to test metformin's effect
- 2:52Speaker 2: on delaying age-related diseases in older adults without diabetes. That's
- 2:57Speaker 2: a big task, and the results are pending.
- 2:59Speaker 1: So, it's clear that more research is needed to fully
- 3:02Speaker 1: understand metformin's role in aging. The variations in how it
- 3:06Speaker 1: works across species and populations make it challenging, but it's
- 3:10Speaker 1: exciting to see this drug taking on a new chapter
- 3:13Speaker 1: in medical research.
- 3:14Speaker 2: Exactly exciting and complex. It's a reminder that while we
- 3:19Speaker 2: are making strides, Therese still much we don't know. The
- 3:23Speaker 2: journey to understand metformin's true potential continues.
- 3:26Speaker 1: Let's dive into the nitty-gritty of how metformin works at
- 3:29Speaker 1: a molecular level. Metformin has a profound effect on our cells,
- 3:34Speaker 1: particularly through its interaction with mitochondria, and that sets the
- 3:37Speaker 1: stage for all the other cellular processes it influences.
- 3:41Speaker 2: Right, and that's the crucial nuance. Mitochondria are like powerhouses
- 3:46Speaker 2: of the cell. And metformin tweaks their output. Specifically, it
- 3:51Speaker 2: seems to shift the metabolic state from glycolysis to lipolysis,
- 3:55Speaker 2: which is a key mechanism in its action.
- 3:58Speaker 1: Exactly. But this isn't just about energy production. Metformin also
- 4:02Speaker 1: activates AMP-activated protein kinase, AMPK. You know, the enzyme that's
- 4:07Speaker 1: really the gateway to so many downstream effects. AMPK gets
- 4:11Speaker 1: activated when ATP levels are low. essentially telling the cell
- 4:15Speaker 1: to save energy.
- 4:16Speaker 2: Yes, and once amki is on, it starts the chain reaction.
- 4:20Speaker 2: One of the first things it does is tamp down
- 4:22Speaker 2: on mammalian target of rapamycin mantoor, which is a big
- 4:25Speaker 2: inhibitor of longevity. By lowering mantoor, amki helps promote autophagy,
- 4:31Speaker 2: that self-cleaning process in cells that discards damaged parts, essentially
- 4:36Speaker 2: keeping the machinery running smoothly.
- 4:38Speaker 1: Absolutely. Autophagy is a cornerstone of aging research. It's one
- 4:43Speaker 1: of those processes that breaks down and recycles old parts.
- 4:47Speaker 1: Metformin enhances this process, making sure the cell stays efficient.
- 4:52Speaker 1: But that's not all. It also has a powerful effect
- 4:55Speaker 1: on insulin sensitivity. Metformin reduces the liver's ability to produce glucose,
- 5:01Speaker 1: which helps the body use insulin better.
- 5:03Speaker 2: That's a big deal because better insulin sensitivity can prevent
- 5:06Speaker 2: some of the metabolic issues that often come with aging.
- 5:10Speaker 2: and it goes beyond just blood sugar control. Metformin might
- 5:15Speaker 2: even change gene expression, leading to slower aging, but the
- 5:18Speaker 2: human evidence on that is still scant.
- 5:21Speaker 1: True, but the studies in worms and mice are intriguing.
- 5:25Speaker 1: In those species, metformin seems to slow the biological markers
- 5:29Speaker 1: of aging, leading to extended lifespans. For instance, a 40-month
- 5:35Speaker 1: study found that metformin increased the health span and lifespan
- 5:40Speaker 1: of male sinomolgus monkeys. That's a substantial finding.
- 5:45Speaker 2: That's wild when you look at the raw numbers. But
- 5:48Speaker 2: let's not get ahead of ourselves. These results might not
- 5:52Speaker 2: translate directly to humans. The MIMI trial, for example, did
- 5:56Speaker 2: show a reduction in diabetes risk, but didn't prevent other
- 6:00Speaker 2: age-related issues like cancer or heart disease.
- 6:03Speaker 1: Right. And the TAME project, which aims to test metformin's
- 6:07Speaker 1: effect in older adults, without diabetes, is still pending its results.
- 6:13Speaker 1: This shows us the complexities. It's not just about extending life,
- 6:17Speaker 1: but also about improving quality of life.
- 6:20Speaker 2: Exactly. And don't forget there are side effects to consider.
- 6:24Speaker 2: Metformin can cause gastrointestinal upset and other issues, which may
- 6:29Speaker 2: limit its widespread use. Plus, the right dosage and treatment
- 6:32Speaker 2: timing are still being figured out.
- 6:34Speaker 1: That's why more research is so vital. We are touching
- 6:38Speaker 1: on so many different cellular pathways and processes, and each
- 6:42Speaker 1: one has implications for how we age. It's a fascinating
- 6:46Speaker 1: glimpse into the future of anti-aging therapies. So, let's talk
- 6:50Speaker 1: about the TAME project. This is a pivotal study aimed
- 6:54Speaker 1: at evaluating metformin's potential to delay the onset of age-related diseases.
- 7:00Speaker 1: It's pretty exciting because the goal isn't just extending life.
- 7:03Speaker 1: but ensuring its quality.
- 7:04Speaker 2: Absolutely, and it's worth noting that the TAME project is
- 7:08Speaker 2: focusing on older adults without diabetes, which is a critical demographic.
- 7:13Speaker 2: After all, it's one thing to find that a drug
- 7:15Speaker 2: works in worms or even mice, but human trials are
- 7:19Speaker 2: where things get tricky.
- 7:20Speaker 1: True. Another study, the MEMIN trial, was promising in that
- 7:25Speaker 1: it did show metformin reduced the incidence of type 2 diabetes.
- 7:30Speaker 1: But interestingly, it didn't really prevent other issues like heart disease, cancer,
- 7:35Speaker 1: or death. This complexity highlights how different the human body
- 7:40Speaker 1: is from simpler organisms.
- 7:42Speaker 2: Exactly. The differences in outcomes across species can be misleading.
- 7:47Speaker 2: For instance, worms and mice may respond differently to metformin
- 7:51Speaker 2: because of their simpler biological systems. It's not just a
- 7:55Speaker 2: linear progression from lab tests to human studies. Right.
- 7:58Speaker 1: And let's dive into the biological underpinnings. Metformin seems to
- 8:02Speaker 1: tweak the balance of energy usage in cells by influencing
- 8:06Speaker 1: mitochondria and activating AMPK, which then modulates mentor and boosts autophagy.
- 8:12Speaker 1: This sounds like a lot of fancy biochemistry, but essentially
- 8:17Speaker 1: it's about cleaning up the cellular house and boosting efficiency.
- 8:20Speaker 2: That's a good point. And for some individuals, especially those
- 8:24Speaker 2: with a predisposition to metabolic issues, Metformin might indeed provide
- 8:28Speaker 2: a silver lining, but as for aging, the evidence isn't
- 8:32Speaker 2: as clear. There are some hopeful indicators in terms of
- 8:35Speaker 2: reduced inflammation and better insulin sensitivity, but in humans it's
- 8:40Speaker 2: still an open question.
- 8:42Speaker 1: Agreed. And let's not forget that metformin isn't without its downsides.
- 8:47Speaker 1: Side effects like nausea, diarrhea, and possible vitamin B12 deficiencies
- 8:52Speaker 1: are well-documented. then to raise the risk of lactic acidosis
- 8:56Speaker 1: for those with weakened kidneys. It's a fine line between
- 9:00Speaker 1: benefit and harm.
- 9:01Speaker 2: Precisely. The challenge lies in finding the right dosage and
- 9:05Speaker 2: identifying the population that could truly benefit. Plus, the right
- 9:10Speaker 2: age to start is another wild card. Some studies suggest
- 9:14Speaker 2: starting metformin early might offer more benefits, but we need
- 9:17Speaker 2: more data to say for sure.
- 9:19Speaker 1: And this all comes back to the broader question of
- 9:21Speaker 1: metformin as an anti-aging drug. While it shows promise in
- 9:25Speaker 1: certain health markers, it's far from conclusively proven to extend
- 9:29Speaker 1: healthy lifespan in humans. And that brings us to the
- 9:33Speaker 1: human studies, where mixed results dominate and observational evidence isn't
- 9:38Speaker 1: enough to claim causality.
- 9:40Speaker 2: Indeed, it's a complex picture. The key takeaway is that
- 9:44Speaker 2: while metformin is a powerful tool in managing type 2
- 9:47Speaker 2: diabetes and some metabolic issues, its role in healthy aging
- 9:51Speaker 2: is still being hashed out. The journey to understand this
- 9:55Speaker 2: drug fully is ongoing.
- 9:56Speaker 1: So, let's dig into the elephant in the room. the
- 9:59Speaker 1: potential side effects, and long-term risks of metformin. One of
- 10:04Speaker 1: the most pressing concerns is vitamin B12 deficiency. How does
- 10:09Speaker 1: metformin cause this?
- 10:10Speaker 2: That's a great question. Metformin works by suppressing glucose production
- 10:15Speaker 2: and enhancing insulin sensitivity. But this mechanism can inadvertently lead
- 10:21Speaker 2: to a vitamin B12 deficiency. The drug can affect the
- 10:24Speaker 2: lining of the stomach, reducing the cells responsible for producing
- 10:28Speaker 2: intrinsic factor, which is essential for absorbing vitamin B12.
- 10:33Speaker 1: Right? And that's the crucial nuance here. So, people on
- 10:37Speaker 1: metformin for a long time might need to supplement their
- 10:40Speaker 1: diet with vitamin B12 to prevent this deficiency. But how
- 10:44Speaker 1: common is this side effect?
- 10:46Speaker 2: Studies show that around 10 to 30% of long-term users
- 10:50Speaker 2: develop a deficiency, but it's more prevalent in those with
- 10:54Speaker 2: certain conditions. For instance, individuals with pre-existing stomach issues or
- 11:00Speaker 2: those taking other drugs that affect gut health might be
- 11:03Speaker 2: at higher risk.
- 11:04Speaker 1: That's an important point. Now, let's talk about lactic acidosis.
- 11:09Speaker 1: Can you explain how metformin might contribute to this condition?
- 11:13Speaker 2: Sure. Metformin can build up lactic acid levels in the blood,
- 11:17Speaker 2: especially in individuals with kidney issues. The kidneys play a
- 11:21Speaker 2: crucial role in clearing lactic acid, and their compromised function
- 11:25Speaker 2: can lead to a dangerous accumulation. This is why regular
- 11:28Speaker 2: kidney function tests are important for anyone on long-term metformin therapy.
- 11:32Speaker 1: Exactly. This brings up an interesting contradiction. Metformin can help
- 11:37Speaker 1: with diabetes, but might be harmful in cases where the
- 11:40Speaker 1: kidneys are already weakened. that's a tough one for healthcare
- 11:44Speaker 1: providers to balance.
- 11:46Speaker 2: Absolutely. It's a double-edged sword. The varying impact of metformin
- 11:51Speaker 2: across different populations is another factor. For instance, certain genetic
- 11:57Speaker 2: predispositions might make individuals more susceptible to side effects, while
- 12:01Speaker 2: others might benefit more from the drug's anti-inflammatory effects.
- 12:05Speaker 1: Right. And speaking of genetic predispositions, a recent study by Mana, Elasmar,
- 12:11Speaker 1: and Elhaj highlighted how metformin might slow the aging clock
- 12:15Speaker 1: through epigenetic changes. But does this apply universally, or do
- 12:20Speaker 1: different groups react differently?
- 12:22Speaker 2: The study indeed suggests that metformin might influence gene expression
- 12:26Speaker 2: in a way that could slow aging, but the evidence
- 12:29Speaker 2: is still preliminary. For example, the effects might be more
- 12:33Speaker 2: pronounced in individuals with certain genetic backgrounds. More research is
- 12:37Speaker 2: needed to pinpoint these differences.
- 12:39Speaker 1: That's where things get complex. Given the varying impact and
- 12:43Speaker 1: potential side effects, how do healthcare providers decide who's a
- 12:48Speaker 1: good candidate for long-term metformin use?
- 12:51Speaker 2: It's a case-by-case basis. Providers typically assess the patient's overall health,
- 12:56Speaker 2: existing conditions, and genetic factors. They might also look at
- 13:00Speaker 2: the patient's lifestyle and diet to determine the best course
- 13:03Speaker 2: of action. The goal is to weigh the potential benefits
- 13:07Speaker 2: against the risks.
- 13:08Speaker 1: Exactly. And this all comes down to individualized care. With metformin,
- 13:14Speaker 1: it's not a one-size-fits-all solution. The journey to fully understand
- 13:18Speaker 1: and optimize its benefits for healthy aging is ongoing. So,
- 13:22Speaker 1: as we wrap up this discussion on metformin and healthy aging,
- 13:25Speaker 1: it's clear that here's a lot to unpack. Let's start
- 13:29Speaker 1: by discussing the current state of research. What do we
- 13:32Speaker 1: know for certain?
- 13:33Speaker 2: Well, Rachel, the research is definitely mixed. Metformin shows promise
- 13:38Speaker 2: in a variety of aging-related processes, like improving insulin sensitivity
- 13:42Speaker 2: and potentially altering gene expression, but these effects seem to
- 13:45Speaker 2: vary quite a bit among different species and populations. For instance,
- 13:50Speaker 2: some worms in mice show extended lifespans, but experiments with
- 13:54Speaker 2: monkeys didn't replicate that outcome as clearly.
- 13:56Speaker 1: Right. And that brings up a key challenge. How do
- 14:00Speaker 1: we determine which populations might benefit the most from long-term
- 14:04Speaker 1: metformin use? It's not a one-size-fits-all solution.
- 14:09Speaker 2: Exactly. There are still significant challenges in determining the right dosage,
- 14:14Speaker 2: age to start, and treatment duration. Take the TAME project,
- 14:18Speaker 2: which is a $ 184 million trial in the United States.
- 14:23Speaker 2: The goal is to see if metformin can delay the
- 14:25Speaker 2: onset of age-related diseases, but the outcomes are still pending.
- 14:30Speaker 1: And it's not just about the outcomes. Studies measure different things,
- 14:34Speaker 1: incidence of cancer, heart disease, frailty, and even biological markers
- 14:39Speaker 1: of aging. It's hard to get a clear picture of
- 14:42Speaker 1: what exactly metformin could do to extend a healthy lifespan.
- 14:46Speaker 2: That's a good point. The MEMIM trial, for example, showed
- 14:50Speaker 2: that metformin reduced the incidence of type 2 diabetes but
- 14:54Speaker 2: didn't prevent other health issues. Another trial for older adults
- 14:58Speaker 2: with muscle loss and frailty found minimal impact on physical
- 15:01Speaker 2: performance even though the subjects have been taking metformin for years.
- 15:06Speaker 1: And we shouldn't forget the side effects. Long-term use can
- 15:10Speaker 1: lead to issues like nausea, diarrhea, and B12 deficiency, which
- 15:15Speaker 1: can impact overall health in significant ways. It's crucial to
- 15:20Speaker 1: manage these risks.
- 15:22Speaker 2: Absolutely. Metformin can also cause lactic acidosis in individuals with
- 15:27Speaker 2: weakened kidneys, which is a serious concern. So, the key
- 15:31Speaker 2: is to identify the right candidates, and this is where
- 15:34Speaker 2: personalized medicine comes in. Providers need to carefully assess each
- 15:38Speaker 2: patient's history and health status before deciding if metformin is appropriate.
- 15:42Speaker 1: Yes, it's not just about the drug itself. The future
- 15:46Speaker 1: of metformin and healthy aging hinges on better understanding which
- 15:50Speaker 1: populations might see the most benefit. Maybe genetics play a
- 15:54Speaker 1: big role, or perhaps we need to look at lifestyle
- 15:57Speaker 1: factors and environmental influences. Therese, still so much to explore.
- 16:02Speaker 2: Agreed. The next phase of research will likely involve more
- 16:06Speaker 2: personalized approaches. We need to delve deeper into epigenetics and
- 16:10Speaker 2: how metformin might work differently depending on individual genetic profiles.
- 16:15Speaker 2: Therese also the potential for metformin to work best when
- 16:18Speaker 2: combined with other interventions, like diet and exercise.
- 16:21Speaker 1: True. And as research continues, we might find new ways
- 16:25Speaker 1: to optimize metformin's benefits. The journey to fully understanding its
- 16:30Speaker 1: effects on healthy aging is just beginning. What do you
- 16:35Speaker 1: think the next big breakthrough could be in this field?
- 16:37Speaker 2: Possibly a deeper understanding of metformin's interaction with the gut microbiome.
- 16:43Speaker 2: We know it can affect the production of short-chain fatty acids,
- 16:47Speaker 2: which in turn influence inflammation and insulin response. If we
- 16:52Speaker 2: can harness this, it could lead to some exciting new
- 16:54Speaker 2: applications for metformin.
- 16:56Speaker 1: And who knows? We might even find ways to replicate
- 16:59Speaker 1: the beneficial effects of metformin in a more targeted manner.
- 17:03Speaker 1: But for now, the key takeaway is that while metformin
- 17:06Speaker 1: shows promise, we need more rigorous, controlled human trials to
- 17:11Speaker 1: truly understand its potential in healthy aging.
- 17:14Speaker 2: Exactly. It's a complex landscape, but one that holds great promise.
- 17:20Speaker 2: As always, the road to discovery is full of challenges.
- 17:23Speaker 2: but that's part of what makes it so exciting.
- 17:26Speaker 1: That brings us to the end of today's episode. Thank
- 17:28Speaker 1: you so much for spending part of your day with me.
- 17:31Speaker 1: If you found this episode's tips helpful and want to
- 17:33Speaker 1: make sure you don't miss the next conversation, please take
- 17:36Speaker 1: a quick second to hit that subscribe or follow button
- 17:39Speaker 1: on whatever platform you are listening on. It's a completely
- 17:42Speaker 1: free way to support the show and helps more people
- 17:45Speaker 1: find us. This podcast is independently produced, so if you
- 17:49Speaker 1: are ever in a position where you would like to
- 17:50Speaker 1: help keep it running, we do accept small donations. You
- 17:55Speaker 1: can find a link right in the episode description below
- 17:58Speaker 1: to buy us a coffee or contribute what you can.
- 18:01Speaker 1: Every bit genuinely helps. Take care of yourself, stay balanced,
- 18:05Speaker 1: and we will talk again soon.